Sarilumab Doses for Early Polymyalgia Rheumatica

The study aims to find out if the medication sarilumab, given at two different doses, is effective and safe for adults who have early polymyalgia rheumatica (PMR), a condition that causes muscle pain and stiffness. This study is important because it could offer a new treatment option for people with PMR, potentially improving their quality of life. The study involves comparing sarilumab to a placebo, both combined with a 52-week course of prednisone, a common steroid medication used to treat PMR. By exploring these treatment options, the study hopes to address the ongoing need for effective PMR treatments. Participants in the study will be randomly assigned to receive either 150 mg or 200 mg of sarilumab every two weeks or a placebo, along with a gradual reduction of prednisone over 52 weeks. The study will run over multiple visits, starting with a screening visit, followed by the first dose and baseline measurements, and continuing through regular treatment visits. The effectiveness of the treatment will be evaluated by checking for sustained remission, meaning no signs or symptoms of PMR, at the end of the study period. The study will also monitor any potential side effects to ensure the safety of the treatments.